Inspired by the DIREct-On study, we designed this multicenter prospective observational clinical trial to explore multimodal models that were more feasible in the clinical routine for predicting DCB of ICI treatments in non-EGFR/ALK NSCLC patients. Here, ALK is linked to non-small cell lung carcinoma.